PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker.PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization.PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.
《药物经济学》是一本基准期刊，发表关于药物经济学和生活质量评估在优化药物治疗和健康结局方面的应用的同行评议、权威和实用文章。为医疗保健决策者提供应用药物经济学原创研究和教育材料的无价来源。药物经济学致力于与患者护理和药物利用相关的复杂药物经济学问题的清晰沟通。药物经济学提供了一系列额外的功能，旨在增加期刊内容的可见性、读者群和教育价值。每篇文章都附有一个要点摘要，为广大读者提供了一个省时的内容概述。文章可能附有简明扼要的语言摘要，以帮助读者了解该领域的一些知识，但不是深入的专业知识，以理解文章的科学内容和整体含义。
Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00768-7
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00806-4
Transparency in Decision Modelling: What, Why, Who and How?
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00819-z
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00774-9
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00800-w
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00788-3
Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00782-9
Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00775-8
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00781-w
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00851-z
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00825-1
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00845-x
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00802-8
Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00786-5
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00855-9
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00844-y
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00839-9
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00834-0
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00848-8
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00862-w
Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00863-9
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00869-3
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00870-w
Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00875-5
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00815-3
Cooking Up a Transparent Model Following a DICE Recipe
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00840-2
Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00766-9
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00808-2
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00798-1
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00841-1
Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00783-8
Improving Transparency in Decision Models: Current Issues and Potential Solutions
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00850-0
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00847-9
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00853-x
Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00767-8
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00813-5
Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00874-6
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00857-7
Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00776-7
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00835-z
Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00861-x
Transferability of Economic Evaluations of Treatments for Advanced Melanoma
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00860-y
Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00778-5
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00821-5
